NCT06227897 (AERESA) is a Phase 2 clinical trial of Aumolertinib in Lung Cancer, sponsored by Sun Yat-sen University.

Who is sponsoring NCT06227897?

NCT06227897 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT06227897?

Interventions in NCT06227897: Aumolertinib.

What condition does NCT06227897 study?

NCT06227897 studies Lung Cancer.

Is NCT06227897 still recruiting?

NCT06227897 is currently withdrawn. Last updated 10 December 2024.

Last reviewed 2024-12-10 · How we verify

NCT06227897: AERESA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).

Withdrawn Phase 2 Last updated 10 December 2024

What this trial tests

Phase 2 trial testing Aumolertinib in Lung Cancer. Withdrawn.

Timeline

1 June 2024

Primary endpoint
1 April 2026

1 April 2029

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	1 June 2024
Primary completion	1 April 2026
Estimated completion	1 April 2029
Sites	1 location across China

Drugs / interventions tested

Aumolertinib — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Sun Yat-sen University

Who can join

Adults 18 to 75, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aumolertinib (almonertinib; HS-10296) is a novel third-generation EGFR-TKI showing activity against EGFR-sensitizing mutations and EGFR T790M mutation. The third-generation EGFR-TKI osimertinib has been approved in the adjuvant setting. This study is to studying 3-year aumolertinib as adjuvant therapy to see how well it works in treating patients with resected stage IB-IIIA NSCLC harboring sensitizing EGFR mutations.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.
Fuorivia V, Attili I, Corvaja C, Asnaghi R, et al · · 2024 · cited 7× · PMID 39330007 · DOI 10.3390/curroncol31090379

Verify or expand the search:

Other trials of Aumolertinib

Trials testing the same drug.

NCT06752408 — Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non- · Phase 2 · not yet recruiting
NCT07130916 — A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer · Phase 1 · recruiting
NCT06417008 — A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer · Phase 2, PHASE3 · recruiting
NCT05946460 — Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity. · Phase 2 · unknown
NCT04922138 — Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns · Phase 2 · unknown

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06227897 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 10 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06227897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing